Ferrata Storti Foundation C hronic myeloid leukemia is caused by a balanced chromosomal translocation resulting in the formation of BCR-ABL1 fusion gene encoding a constitutively active BCR-ABL1 tyrosine kinase, which activates multiple signal transduction pathways leading to malignant transformation. Standard treatment of chronic myeloid leukemia is based on tyrosine kinase inhibitors; however, some mutations have proven elusive particularly the T315I mutation. Drosophila melanogaster is an established in vivo model for human diseases including cancer. The targeted expression of chimeric human/fly and full human BCR-ABL1 in Drosophila eyes has been shown to result in detrimental effects. In this study, we expressed human BCR-ABL1 p210 and the resistant BCR-ABL1 p210/T315I fusion oncogenes in Drosophila eyes. Expression of BCR-ABL1 p210/T315I resulted in a severe distortion of the ommatidial architecture of adult eyes with a more prominent rough eye phenotype compared to milder phenotypes in BCR-ABL1 p210 reflecting a stronger oncogenic potential of the mutant. We then assessed the efficacy of the currently used tyrosine kinase inhibitors in BCR-ABL1 p210 and BCR-ABL1 p210/T315I expressing flies. Treatment of BCR-ABL1 p210 expressing flies with potent kinase inhibitors (dasatinib and ponatinib) resulted in the rescue of ommatidial loss and the restoration of normal development. Taken together, we provide a chronic myeloid leukemia tailored BCR-ABL1 p210 and BCR-ABL1 p210/T315I fly model which can be used to test new compounds with improved therapeutic indices.
Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm secondary to a precise cytogenetic abnormality involving a balanced chromosomal translocation between the Abelson murine leukemia (ABL1) gene on chromosome 9 and the breakpoint cluster region (BCR) on chromosome 22. This creates the (BCR-ABL1) fusion gene on chromosome 22 which encodes a constitutively active tyrosine kinase BCR-ABL. 1 Based on the breakpoints in BCR this translocation results in the formation of (p190, p210 and p230) fusion genes. 2 Overall, 95% of CML patients harbor the p210-kDa fusion protein, BCR-ABL1 p210 . 3, 4 The BCR-ABL1 fusion oncoprotein increases the replication machinery and enhances cell growth which is mediated by downstream signaling pathways such as RAS, RAF, JUN kinase, MYC and STAT. [5] [6] [7] [8] [9] [10] [11] CML treatment was revolutionized with the development of tyrosine kinase inhibitors (TKI) which competitively inhibit the Adenosine triphosphate (ATP) binding site in the BCR-ABL1 kinase domain 12 and hence block the phosphorylation of proteins in the downstream signaling cascade. The first generation TKI (imatinib) showed major therapeutic improvement in the IRIS study (International Randomized Study of Interferon and STI571). 13 However, imatinib success was outshined by the emergence of resistance caused by point mutations in the ABL1 kinase domain which necessitated the development of second-generation TKI. 14,15 Dasatinib [16] [17] [18] and nilotinib [19] [20] [21] revealed faster and deeper molecular responses compared to imatinib in patients with newly diagnosed chronic phase CML. In vitro, dasatinib is more potent than imatinib [22] [23] [24] and inhibits a wider spectrum of kinases including the Src family. 25 Nilotinib has a greater affinity than imatinib to the ATP binding site in BCR-ABL1 and its spectrum of kinase inhibition involves platelet-derived growth factor receptor (PDGFR) and c-Kit receptors. 26 Although nilotinib and dasatinib tackled the majority of imatinib-resistant mutations, neither of them targeted the T315I mutation (threonine to isoleucine substitution at position 315 in the ABL1 kinase domain) (BCR -ABL1   T315I   ) . 23 Ponatinib, a third generation TKI, remains the only clinically available drug that is designed to overcome the T315I gatekeeper mutation. 27, 28 However, post-marketing safety issues with ponatinib involved serious cardiovascular events which led to its temporary suspension and then reintroduction with special patient recommendations. 29, 30 In addition to the burden of resistance, therapy with TKI is hindered by their inability to eradicate leukemic stem cells and hence relapse often accompanies discontinuation of therapy. 31 This fact imparts lifelong therapy with TKI despite accompanying side effects which result in ever-expanding costs for remission sustainment. Therefore, it seems evident that despite the breakthrough with TKI, CML remains a pathology that requires vigilant assessment of curative therapeutic interventions.
One simple, multicellular and genetically tractable animal model that has been exploited in recent years for modelling human diseases, including cancer, is Drosophila melanogaster. 32 A myriad of advantages is held by this 3 mm long fruit fly as an in vivo model for dissecting the contribution of cellular mechanisms to human cancers and therapeutic screening. Fogerty et al. utilized Drosophila to decipher functional analogies between fly ABL1 and human BCR-ABL1 via neural-specific expression of p185 or p210 BCR-ABL1 transgenes. In these transgenes, BCR and the N-terminal sequences are derived from human oncogenes while the C-terminal ABL1 tail is from Drosophila. Both transgenes were capable to substitute the fruit fly ABL1 during axon genesis and flies expressing BCR-ABL1 revealed an increase in the phosphorylation of Enabled (Ena), a substrate for Drosophila Abl (dAbl). Expression of chimeric BCR-ABL1 in Drosophila eyes and CNS resulted in a rough eye phenotype and CNS developmental defects. 33 Furthermore, a recent study showed that the expression of human BCR-ABL1 p210 in Drosophila activates the dAbl pathway and its upstream regulators Ena and Disabled (Dab). 34 In this study, we have overexpressed human BCR-ABL1 p210 and mutated BCR-ABL1 p210/T315I in Drosophila compound eyes. BCR-ABL1 p210/T315I expression induced a significantly more severe rough eye phenotype compared to BCR-ABL1 p210 pointing towards more aggressive tumorigenic capacities of the gatekeeper mutation. We have further assessed the efficiency of the current TKI used in clinics in modifying the characteristic eye phenotypes of transgenic flies. Dasatinib and ponatinib rescued the eye defects observed upon expression of BCR-ABL1 p210 making this model a valuable screening platform to pre-clinically evaluate the efficacy of potential novel therapies for CML.
Methods

Fly stocks
Fly stocks were maintained at 25ºC on standard agar-based medium. GMR-GAL4 (BDSC 1104) were obtained from Bloomington Stock Center. Treatment was performed at 18ºC. Fly work was done following the institutional guide for the care and use of laboratory animals.
Generation of transgenic flies
Transgenic flies, harboring human BCR-ABL1 p210 and BCR-ABL1 p210/T315I were generated using Phi C31 integrase system and were inserted in the 3 rd chromosome for GAL4-UAS expression. BCR-ABL1 p210 and BCR-ABL1 p210/T315I were inserted into pUASTattB Drosophila expression vector (Custom DNA cloning). pUAST-attB-myc BCR-ABL1 p210 and pUAST-attB-myc BCR-ABL1 p210/T315I were injected into y1 w67c23; P {CaryP} ABLattP2 (8622 BDSC) embryos to generate transgenic flies (BestGene Inc, Chino Hills, CA).
TKI administration
Imatinib (I-5577), nilotinib (N-8207), dasatinib (D-3307) and ponatinib (P-7022) were obtained from LC laboratories, MA, USA. Stock solutions were dissolved in DMSO and the required amount of TKI was added to instant Drosophila medium (Carolina Biological Supply Company). Since DMSO is known to be toxic to Drosophila, 40 0.03% DMSO was used for low TKI concentrations and 0.3% for high concentrations.
Scoring of eye phenotypes and measurement of eye defect area
A grading score, that was modified from the score previously published, 35 was used for scoring and is based on the number of ommatidial fusions, the extent of bristle organization and ommatidial loss (Online Supplementary Table S1 ). For the measurement of the posterior eye defect area, Image J 36 was used. Scanning electron microscopy images were coded by one researcher and analysis was blindly performed by another researcher. N=20 flies from each genotype at each temperature were scored and the experiment was done in triplicate. For the measurement of posterior eye defect area an average of n=20-30 flies from each group was quantified and the experiment was done at least twice.
Scanning electron microscopy (SEM)
Adult flies were fixed in 2% glutaraldehyde and 2% formaldehyde in phosphate buffered saline (PBS) (1x), washed, dehydrated with a series of increasing ethanol concentrations, dried with a critical point dryer (k850, Quorum Technologies), mounted on standard aluminum heads and coated with 20 nm layer of gold. Analysis was performed using Tescan, Mira III LMU, Field Emission Gun (FEG) SEM with a secondary electron detector.
Western blot analysis
Fly heads were homogenized in Laemmli buffer and samples were loaded in 8% SDS-PAGE. Anti-ABL1 (SC-23, 1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) and phospho-ABL1 (#2868, 1:500, Cell Signaling Technology) primary antibodies and antimouse (SC-2318, 1:5000, Santa Cruz Biotechnology, Santa Cruz, CA) and anti-rabbit (NA934, 1:5000, GE Healthcare) secondary antibodies were used for protein detection. An extract (150 µg) from 20-30 flies was used.
Statistical analysis
The statistical significance of the difference between the average scores of the rough eye phenotype and the average scores of the posterior eye defect area was evaluated using two-way analysis of variance (ANOVA) followed by the Tukey's multiple comparisons test. One-way ANOVA was used when comparing the averages of the posterior eye defect area for dose response and was followed by Tukey's multiple comparisons test. Associations with p < 0.05 were considered significant. Statistical tests were done using GraphPad Prism 6.0 software.
Results
Expression of human BCR-ABL1 in Drosophila eyes induces transformation
To assess the transformative potential of human BCR-ABL1 p210 and BCR-ABL1 p210/T315I in Drosophila, we expressed the transgenes in the adult eye using the glassmultimer reporter promoter GMR-GAL4 which drives the expression in all differentiating photoreceptor cells posterior to the morphogenetic furrow. 37 GMR-GAL4>w 1118 flies were used as a control. The temperature sensitivity of the GAL4-UAS system allowed us to the control BCR-ABL1 expression levels. 38 Therefore crosses were performed at 18ºC, 25ºC, and 29ºC allowing for a reciprocal increase in transgene expression upon increased temperatures. Enclosed flies were imaged using light microscopy and SEM and evaluations of phenotypes were performed using a grading score (Online Supplementary Table S1 ) which graded the severity of the phenotype based on the extent of mechano-sensory bristles alignment, misplacement and duplication as well as the extent of ommatidial facets loss indicating the disruption in cellular proliferation and differentiation collectively defining interrupted normal development. 39 BCR-ABL1 p210 and BCR-ABL1 p210/T315I
showed a rough eye phenotype with increased severity at a higher temperature compared to control flies. At 18ºC BCR-ABL1 p210 and BCR-ABL1 p210/T315I flies exhibited a rough eye phenotype characterized by ommatidial fusions and areas of lost ommatidial facets, particularly at the posterior end of the eye, as well as multiple ectopic mechanosensory bristles which are duplicated at some instances (Figure 1 , the average roughness significantly increased from 6.6 at 18ºC to 8.9 (P<0.0001) at 25ºC and to 10 (P<0.0001) at 29ºC (Figure 2 ). Western blot analysis confirmed the expression and phosphorylation of BCR-ABL1 p210 and BCR-ABL1 p210/T315I in Drosophila eyes (Figure 3 ).
Dasatinib and ponatinib rescue human BCR-ABL1
p210 mediated defects in Drosophila
Since expression of BCR-ABL1 at high temperature induced severe eye defects in adult flies, we opted to use the lowest temperature (18°C) which produced milder phenotypes for TKI screening efficiency allowing the easy visualization of any rescue due to drug activity. Four TKI were tested which included imatinib, nilotinib, dasatinib and ponatinib. BCR-ABL1 p210 flies were crossed to GMRGal4 flies and progeny were fed on multiple concentrations of the TKI (treated) or on DMSO alone (untreated). Untreated BCR-ABL1 p210 and BCR-ABL1 p210/T315I flies showed the same defects described previously at 18ºC focusing particularly on the posterior end of the eye with a characteristic defective area characterized by loss of ommatidial facets (Figures 4-6) . The posterior eye defect area in untreated BCR-ABL1 p210 flies showed an average of 4580 mm 2 and 4044 mm 2 on 0.03% DMSO and 0.3% DMSO respectively (Figures 4-6) . On the other hand, untreated BCR-ABL1 p210/T315I expressing flies showed a wider area of defect at the posterior end with an average significant increase in the defect area to 11148 mm 2 (P<0.0001) and 8728 mm 2 (P<0.0001) on 0.03% DMSO and 0.3% DMSO respectively as compared to untreated BCR-ABL1 p210 expressing flies (Figures 4-6 ). Feeding 150 mM or 1500 mM imatinib to BCR-ABL1 p210 expressing flies did not eliminate the posterior eye defect. However, the average posterior eye defect area showed a tendency to decrease with 1500 mM imatinib (3047 mm (Figure 4) . Interestingly, the percentage of flies with total rescue (total disappearance of the posterior eye defect) with 150 mM and 1500 mM imatinib was 4% and 21% respectively. Similarly, feeding 28 mM ((Online Supplementary Figure S1 E, K) or 280 mM (Online Supplementary Figure S1 Figure S1 ). The percentage of flies with total rescue with 28 mM and 280 mM nilotinib was 7% and 13% respectively.
Testing the potent TKI (dasatinib and ponatinib) showed more efficient rescue. Feeding 20 mM dasatinib or 280 µM ponatinib to BCR-ABL1 p210 expressing flies improves the overall eye ommatidial arrangement and more specifically eliminates the characteristic posterior eye defect by restoring its normal ommatidial development ( Figure 5 D, H; Figure 6 D, H). The average posterior eye defect area significantly decreased from 4580 mm 2 (in untreated flies) to 0 mm 2 (P<0.0001) with 20 mM dasatinib ( Figure 5 ) and from 4044 mm 2 (in untreated flies) to 267 mm 2 (P<0.0001) with 280 mM ponatinib ( Figure 6 ). The percentage of flies with total rescue was 100% with dasatinib and 86% with ponatinib.
A dose-response analysis for BCR-ABL1 p210 expressing flies treated with dasatinib showed a significant decrease in the average posterior eye defect area from 4580 mm 2 in untreated flies to 2372 mm 2 (P<0.0001) with 1 mM dasatinib, to 131 mm 2 (P<0.0001) with 10 mM and to 0 mm 2 (P<0.0001) with 20 mM dasatinib. The percentage of flies with total rescue increased from 25% to 92% and to 100% with 1 mM, 10 µm and 20 mM dasatinib respectively ( Figure 7) . Similarly, ponatinib also showed a doseresponse whereby the average posterior eye defect area decreased significantly from 4044 mm 2 in untreated flies to 1684 mm 2 (P<0.0001) with 28 mM and to 267 mm 2 (P<0.0001) with 280 mM ponatinib ( Figure 7) . The percentage of flies with total rescue increased from 48% to 86% with 28 mM and 280 mM ponatinib respectively. The BCR-ABL1 p210/T315I mutation is known to exhibit resistance to imatinib, nilotinib and dasatinib in CML patients and this was confirmed in our model whereby the characteristic posterior eye defect did not show ommatidial rescue when feeding BCR-ABL1 Figure S1 Q, W, R, X). However, feeding ponatinib to BCR-ABL1 p210/T315I expressing flies did not show the expected rescue of the posterior eye defect ( Figure 6 L, P) . Western blot analysis confirmed the expression and phosphorylation of BCR-ABL1 p210 and BCR-ABL1 p210/T315I in Drosophila eyes from untreated or treated flies (Figures 5-6 ).
A. Al Outa et al.
390
haematologica | 2020; 105(2) 
Discussion
In this study, we established a transgenic Drosophila model expressing human BCR-ABL1 to serve as a credible platform for CML drug screening. Contrary to what has been done previously by Fogerty et al. where chimeric human/fly BCR-ABL1 was expressed in Drosophila 33 we expressed a full human BCR-ABL1 p210 protein. In a recent study, a CML Drosophila model expressing the human BCR-ABL1 p210 was used to study genes and pathways that play a role in CML onset and progression. 34 The Drosophila eye, with its highly organized reiterative ommatidial structure, constitutes an efficient and relatively easy read out capable of amplifying subtle changes caused by disturbance to normal development. Therefore, we chose this epithelial monolayer as a target tissue for A CML Drosophila model for treatment screening haematologica | 2020; 105 (2) 391 expressing human BCR-ABL1 p210 and human BCR-ABL1 p210/T315I . Bernardoni et al. 34 recently showed that expression of human BCR-ABL1 p210 in Drosophila eyes was destructive to the normal eye development and resulted in a "glazy" eye phenotype as demonstrated by light microscopy images. We went further to investigate the effect of increased temperature on transgene expression as well as used SEM analysis in addition to light microscopy to show the subtle details of the eye phenotypes. Moreover, we opted to investigate whether one of the most elusive BCR-ABL1 mutations (T315I) behaves similarly or differently to the wild type. We found that, with increased temperature, the rough eye phenotype was more prominent in T315I mutant BCR-ABL1 (Figures 1-2) . To validate our model for treatment screening, we focused on a specific area in the posterior end of the eye which was evident to be defective in both BCR-ABL1 p210 and BCR-ABL1 We further validated the model by assessing the capability of the conventional treatments used in clinics for CML patients of improving the eye defects observed in the adult eyes of BCR-ABL1 p210 and BCR-ABL1 p210/T315I flies. These TKI include imatinib as first generation TKI, nilotinib and dasatinib as second and ponatinib as third generation TKI. Dasatinib and ponatinib resulted in the full rescue of the BCR-ABL1 p210 eye defect (Figures 5-6 ) in 100% and 86% of flies respectively. Imatinib and nilotinib (Figure 4 ; Online Supplementary Figure S1 ) exhibited a lower A. Al Outa et al. 394 haematologica | 2020; 105(2) percentage of rescue, 21% and 13% respectively; this might be attributed to the difference in the drug potencies among to of imatinib and other TKI. Compared to imatinib, Dasatinib exhibits a 325-fold higher potency of BCR-AB1L inhibition in vitro whereas nilotinib is only 20-fold more potent. 23 Another possible explanation for the limited rescuing efficacy of imatinib and nilotinib could be the activation of dAbl by BCR-ABL1 expression shown previously by Bernardoni et al., 34 which demonstrated that human BCR-ABL1 expression interferes with the dAbl signaling pathway and increases Ena phosphorylation, a dAbl target. On the other hand, using Drosophila wing epithelium as an in vivo model, Singh et al. 41 demonstrated that activated dAbl exerts a positive feedback loop on Drosophila Src members leading to an increase in their activity and hence signal amplification. It is well known A CML Drosophila model for treatment screening haematologica | 2020; 105 (2) 395 that both dAbl 42 and Drosophila Src 43 play important roles in Drosophila eye development; therefore it is possible that upon human BCR-ABL1 expression in Drosophila eyes, the dAbl signaling pathway is activated which in its turn activates Drosophila Src members and amplifies BCR-ABL1 mediated effects. Interestingly, Src is one of the kinases inhibited by dasatinib and ponatinib but not imatinib and nilotinib, therefore, this might possibly explain the more robust rescuing effect seen by dasatinib and ponatinib. Dasatinib demonstrated target specificity in vivo whereby BCR-ABL1 p210/T315I flies fed on dasatinib showed the expected resistance to treatment. BCR-ABL1 p210/T315I resistance to imatinib and nilotinib was also confirmed as there was no rescue of ommatidial development. In contrary to what was expected, ponatinib was not successful in rescuing progeny expressing BCR-ABL1 p210/T315I
. While this phenomenon is hard to explain we would like to focus on the fact that the eye defect area was significantly larger upon BCR-ABL1 p210/T315I expression compared to the area upon BCR-ABL1 p210 expression. Noting this significant increase in the average posterior eye defect area, we hypothesize that the phenotype was still very severe to allow for any drug reversal. Moreover, noting that the choice of the dose was limited by DMSO toxicity, the ponatinib dose used may not have been high enough to reverse the defect. On the other hand, we tried to test ponatinib to rescue the unpublished lethality phenotype of BCR-ABL1 p210/T315I flies; interestingly feeding ponatinib to BCR-ABL1 p210/T315I expressing flies rescued larval lethality and allowed development to the pupal stage which suggests that the drug's response is tissue dependent. Feeding ponatinib or dasatinib to BCR-ABL1 p210 expressing flies resulted in the rescue of pupal lethality and enclosure of adult flies (unpublished data).
We propose an in vivo model for BCR-ABL1 driven transformation where we show the efficacy of the current potent treatments in reversing a very subtle phenotype in a specific location in the posterior end of the adult compound eye. This system could be used to assess the efficacy of novel compounds by performing high throughput library testing in vivo. We believe that a Drosophila CML model to screen for potential compounds is required in this field especially as the currently used TKI do not target CML stem cells and hence are not curative.
